• Immune Cells Soak Up Duchenne MD Therapy Exondys 51, Prolonging Its Work, Study Reports
  • Intravenous Delivery of CAP-1002 Shown Effective Ahead of Upcoming HOPE 2 Trial for DMD
  • Advanced Gene-Editing Technology CRISPR-Gold Repairs DMD Mutation in Mice
  • Nerve Control of Breathing Overactive in Duchenne Mice, Suggesting Potential Treatment Target
  • #NORDSummit – Rare Disease Summit to Address Issues Crucial to Duchenne Community
  • Resolaris Improved Muscle Strength of Nearly Two-thirds of FSHD Patients, Phase 1/2 Trial Shows
  • Learning to Love the Little Things in Life
  • Parent Project Muscular Dystrophy to Continue Supporting Certified Duchenne Care Center Program
  • Full 6-Month HOPE Trial Results of Capricor’s CAP-1002 for DMD Presented at Muscle Society Congress
  • Summit Presenting Duchenne Biomarker Validation Data and Details of PhaseOut DMD Trial at Meeting
  • Catabasis’ Edasalonexent Continues to Slow Progression of Duchenne in Extension Trial
  • Sarepta on ‘Mission’ It Intends to Accomplish and Soon, CEO Doug Ingram Says in Interview